Early Phase Cancer Immunotherapy
Sandip Pravin Patel · Razelle Kurzrock
2017年11月 · Springer
電子書
331
頁數
report評分和評論未經驗證 瞭解詳情
關於這本電子書
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
關於作者
Razelle Kurzrock, MD, is Senior Deputy Director for Clinical Science, Chief, Division of Hematology & Oncology, Murray Professor of Medicine, Director, Center for Personalized Cancer Therapy & Clinical Trials Office, University of California, San Diego.
Sandip Patel, MD, is Assistant Professor, Cancer Immunotherapy Program, Experimental Therapeutics (Phase 1 Program), Thoracic Oncology, Division of Hematology & Oncology and Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center.
為這本電子書評分
請分享你的寶貴意見。
閱讀資訊
智能手機和平板電腦
手提電腦和電腦
你可以使用電腦的網絡瀏覽器聆聽在 Google Play 上購買的有聲書。
電子書閱讀器及其他裝置
如要在 Kobo 等電子墨水裝置上閱覽書籍，你需要下載檔案並傳輸到你的裝置。請按照說明中心的詳細指示，將檔案傳輸到支援的電子書閱讀器。
